CHO细胞表达基因工程抗体的研究进展OA北大核心

Genetically engineered antibodies have provided a new therapeutic approach for dis-eases such as tumors,autoimmune diseases and infectious diseases,having a significant clinical appli-cation value.These antibodies,a third-generation antibody,are produced through antibody gene modifi-cation,DNA recombination and protein expression techniques in suitable cells where transcription and translation take place.They possess advantages such as strong plasticity,short preparation cycle,simple operation and lower cost.At present,most approved therapeutic antibodies are produced by Chi-nese hamster ovary cells(CHO),which provide complex post-translational modifications to ensure the activity and stability of antibody drugs.In the process of developing antibody drugs,existing produc-tion platforms still face the challenges,low antibody yields,inconsistent quality and stability and high production costs.The types of genetically engineered antibodies,CHO cells and the design strate-gies of recombinant expression vector for the aim of optimizing the expression system are reviewed,serving as references for higher expression level of antibodies and lower production costs,and meeting the growing demands of the future biopharmaceutical industry.